Affimed from Heidelberg had a ‘formative year’ (hmm) in 2015. Major highlights include raising of €52.6M, expanding to the US and advances in the development of its next-generation antibodies for immuno-oncology.
Affimed is a Biopharma focused on discovering and developing highly targeted cancer immunotherapies. It is also one of our trendiest NASDAQ-listed European Biotechs (and the only one from Germany).
The company closed 2015 with €76.7M – enough money to fund its pipeline until the beginning of 2018 (or at least this is the plan). Key fundraising events were the follow-on offering on the NASDAQ (after a troublesome IPO in 2014), which was brought in €33.5M. Aeris, a long-standing shareholder, also put in an additional €19.1M in October 2015.
From the operations side, Affimed made a strategic move in its expansion towards the US in June, illustrated by some key hirings. These include Caroline Stewart, former Wall Street executive, Oscar Kashala, experienced in oncology development,